Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients

BJU International

Volumn 107, Issue 11, 2011, Pages 1748-1754

  Ploussard, Guillaume ^a   Agamy, Mohammad Ali ^a   Alenda, Olivier ^a   Allory, Yves ^a   Mouracade, Pascal ^a   Vordos, Dimitri ^a   Hoznek, Andras ^a   Abbou, Claude Clément ^a   De La Taille, Alexandre ^a   Salomon, Laurent ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

adjuvant radiotherapy; margin; prostate cancer; prostatectomy; PSA failure

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; SEMINAL VESICLE; SURVIVAL TIME; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79956363454     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09728.x     Document Type: Article

References (29)

1. Chang SS, Cookson MS,. Impact of positive surgical margins after radical prostatectomy. Urology 2006; 68: 249-52 (Pubitemid 44175518)
2. Eastham JA, Kattan MW, Riedel E, et al,. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003; 170: 2292-5 (Pubitemid 37413978)
3. Fitzsimons NJ, Presti JC Jr, Kane CJ, et al,. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 2006; 176: 2453-8 (Pubitemid 44755068)
4. Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC,. Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005; 173: 446-9
5. D'Amico AV, Whittington R, Malkowicz SB, et al,. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-8
6. Karakiewicz PI, Eastham JA, Graefen M, et al,. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005; 66: 1245-50 (Pubitemid 41797299)
7. Wright JL, Dalkin BL, True LD, et al,. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010; 183: 2213-8
8. Salomon L, Anastasiadis AG, Levrel O, et al,. Location of positive surgical margins after retropubic, perineal, and laparoscopic radical prostatectomy for organ-confined prostate cancer. Urology 2003; 61: 386-90 (Pubitemid 36206538)
9. Kupelian P, Katcher J, Levin H, Zippe C, Klein E,. Correlation of clinical and pathologic factors with rising prostate specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249-60 (Pubitemid 26279618)
10. d'Amico AV, Whittington R, Malkowicz SB, et al,. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998; 160: 2096-101 (Pubitemid 128703621)
11. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ,. Radical prostatectomy for adenocarcinoma of the prostate:the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994; 43: 828-33 (Pubitemid 24174473)
12. Grossfeld GD, Chang JJ, Broering JM, et al,. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol 2000; 163: 1171-7 (Pubitemid 30169385)
13. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT,. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-24
14. Orvieto MA, Alsikafi NF, Shalhav AL, et al,. Impact of surgical margin status on long-term cancer control after radical prostatectomy. BJU Int 2006; 98: 1199-203 (Pubitemid 44721224)
15. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM,. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400 (Pubitemid 29190217)
16. Vis A, Schroder FH, van der Kwast TH,. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 2006; 50: 258-65 (Pubitemid 44038060)
17. Freedland SJ, Aronson W, Presti JC Jr, et al,. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol 2003; 169: 2142-61
18. Boorjian SA, Karnes RJ, Crispen PL, et al. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 2010; 183 (3): 1003-9
19. Bolla M, van Poppel H, Collette L, et al,. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8 (Pubitemid 41140332)
20. Thompson IM Jr, Tangen CM, Paradelo J, et al,. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35 (Pubitemid 44749360)
21. Wiegel T, Bottke D, Steiner U, et al,. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-30
22. Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H, Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008; 88: 1-9
23. Loeb S, Roehl KA, Viprakasit DP, Catalona WJ,. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol 2008; 54: 88-96
24. Trock BJ, Han M, Freedland SJ, et al,. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-9 (Pubitemid 351846851)
25. Song DY, Thompson TL, Ramakrishnan V, et al,. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002; 60: 281-7 (Pubitemid 34831773)
26. Epstein JI, Amin M, Boccon-Gibod L, et al,. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005; 216: 34-63
27. Evans JA, Henry PC, Van der Kwast TH, et al,. Interobserver variability between expert urological pathologists for extra-prostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol 2008; 32: 1503-12
28. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2010; 164: 101-5
29. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW,. Time to prostate specific antigen recurrence after radical prostatectomy and; risk of prostate cancer specific mortality. J Urol 2006; 176: 1404-8 (Pubitemid 44307204)